The Priority Review

Category

Regulation

Rules, guidance and how the agencies work.

68 stories ยท page 2 of 6

Stories

  1. FDA releases final guidance on reducing transfusion-transmitted Hepatitis B virus

    FDA announces availability of the final guidance titled "Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus" on November 3, 2026. The guidance supersedes several earlier documents and applies to the collection of Whole Blood and blood components, including Source Plasma.

  2. FDA releases final guidance on potency assurance for cellular and gene therapy products

    The notice, published November 3, 2026, announces the availability of the guidance with docket number FDA-2023-D-4299. It recommends a comprehensive strategy grounded in quality risk management for both investigational and licensed CGT products.

  3. FDA actions, week of November 2, 2026: 3 approvals, 3 rules, 1 proposed rule, 2 notices, 1 announcement

    The FDA published 10 actions in the week of November 2 to 8, 2026: 3 approval announcements, 3 final rules in the Federal Register, 1 proposed rule in the Federal Register, 2 notices in the Federal Register and 1 press announcement.

  4. Roche receives FDA 510(k) clearance for new cobas eplex respiratory pathogen panel 3

    Roche announced the FDA 510(k) clearance of the cobas eplex respiratory pathogen panel 3 (RP3), a flexible syndromic test that detects up to 19 viral and bacterial targets from a single nasopharyngeal swab. The panel offers up to five customizable configurations, requires less than one minute of hands-on time, and delivers results in under two hours.

  5. FDA issues final guidance for cell and gene therapy manufacturers

    The FDA today issued final guidance for cellular and gene therapy (CGT) manufacturers, replacing its 2011 potency testing guidance and recommending a Potency Assurance Strategy for products treating serious or life-threatening conditions. The FDA will host a webinar on December 10, 2026 to help stakeholders understand and implement the guidance.

  6. FDA proposes changes to infant formula nutrient specifications and labeling

    The FDA proposes to amend the minimum and/or maximum levels of iodine, vitamin A, vitamin D, and manganese, change the unit of measure for vitamin A from IU to microgram Retinol Activity Equivalents and for vitamin D from IU to micrograms, and modify labeling requirements. Comments on the rule are due by March 2, 2027.

  7. CMS final rule clarifies oversight of Organ Procurement Organizations

    The Centers for Medicare & Medicaid Services published a final rule that clarifies recertification, competition, and appeals processes for Organ Procurement Organizations. The rule defines unsound medical practices and requires OPOs to have QAPI programs to monitor adverse events.

  8. PRAC starts review of Deanxit and human normal immunoglobulin safety signal

    PRAC has begun a review of Deanxit, a fixed-dose combination for depression and anxiety, after reports of serious neurological and psychiatric side effects. PRAC also started a review of a safety signal concerning increased reporting of hypersensitivity reactions associated with specific batches of human normal immunoglobulin medicines, including Flebogamma DIF, Yimmugo and Gamunex that have been withdrawn.

  9. FDA releases revised draft guidance on drug delivery device performance

    The FDA announced the availability of a revised draft guidance published October 30, 2026. The guidance replaces the draft guidance announced July 1, 2024 and provides recommendations for development and organization of device drug-delivery performance information.

  10. FDA classifies radiology software for fibrotic lung disease as class II

    The FDA finalized an order classifying the radiology software for referral of findings related to fibrotic lung disease as class II with special controls that will be part of the codified language for classification. The agency said the classification provides reasonable assurance of safety and effectiveness and may enhance patients' access to beneficial innovative devices by reducing regulatory burdens.

  11. CMS finalizes 2027 ESRD PPS rule with $297.52 base rate

    On Oct. 28, 2026, CMS issued a final rule that sets the 2027 ESRD PPS base rate at $297.52, an increase of $15.81 from the 2026 rate, and projects a 2.7% rise in total payments to about 7,600 facilities. The rule also updates phosphate binder inclusion, low-volume and pediatric payment adjustments, and the home and self-dialysis training add-on payment.

  12. Sales of Leqembi total 32.2 billion yen in third quarter 2026

    BioArctic AB reported preliminary global revenue for Leqembi of JPY 32.2 billion in the third quarter 2026, generating a royalty of SEK 203.8 million, up about 74 percent from the same period in 2025. The company disclosed the figures under the EU Market Abuse Regulation on October 28 2026.